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Abstract
Background: Recently, CD4
+IL-17A
+ T helper 17 (Th17) cells were identified and reported in several diseased states,
including autoimmunity, infection and various peripheral nervous system tumors. However, the presence of Th17 in glia-
derived tumors of the central nervous system has not been studied.
Methodology/Principal Findings: In this report, we demonstrate that mRNA expression for the Th17 cell cytokine IL-17A, as
well as Th17 cells, are present in human glioma. The mRNA expression for IL-17A in glioma was recapitulated in an
immunocompetent mouse model of malignant glioma. Furthermore, the presence of Th17 cells was confirmed in both
human and mouse glioma. Interestingly, some Th17 cells present in mouse glioma co-expressed the Th1 and Th2 lineage
markers, IFN-c and IL-4, respectively, but predominantly co-expressed the Treg lineage marker FoxP3.
Conclusions: These data confirm the presence of Th17 cells in glia-derived CNS tumors and provide the rationale for further
investigation into the role of Th17 cells in malignant glioma.
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Introduction
Glioma, which is a tumor that arises from a cell with glial lineage
in the central nervous system (CNS), is a categorical designation for
multiple types of glial tumors, including ependymomas, astrocyto-
mas, oligodendrogliomas and glioblastoma multiforme (GBM). Of
note, GBMisa highlymalignant gliomawith poortreatmentoptions
and an average lifespan of 15 months after diagnosis [1]. Recently,
our lab demonstrated that a specific subset of T helper cells,
CD4
+CD25
+ T regulatory (Treg) cells, are increased in human
GBM [2], as well as various grades of astrocytoma [3]. Furthermore,
Treg accumulation is recapitulated in an experimental mouse model
of malignant glioma [4,5]. Additionally, we demonstrated that Treg
depletion in a mouse model of malignant glioma significantly
increases lifespan [4]. Collectively, these data suggest that T helper
subsets, such as Treg, are potential targets for future therapy of
GBM. However, as additional T helper subsets are characterized,
further investigation is required.
Recent work has identified the T helper 17 (Th17) cell subset,
which is characterized as CD4
+ T cells that produce large amounts
of IL-17A (CD4
+IL-17A
+) [6]. Similar to Tregs, which differen-
tiate in the presence of transforming growth factor-beta (TGF-b),
Th17 differentiate in the combined presence of TGF-b and
interleukin-6 (IL-6) [7]. In contrast to Tregs, Th17 require the
additional cytokine, IL-23, for pathogenic activation [8]. The
presence of Th17 cells has been demonstrated in autoimmune
pathology [9], infectious inflammatory states [10] and tumor
microenvironment [11]. Thus far, Th17 cells have not been
reported to be exclusive to any one type of malignancy, as they
have been observed in human ovarian-, colon- and breast-cancer,
as well as melanoma [12]. However, the presence of Th17 cells in
primary brain tumors has not been reported. This is particularly
relevant since tumors that form in the CNS are shielded from
effective T cell-mediated immunity [13], which is likely attribut-
able due to the lack of a lymphatic system and presence of the
blood-brain-barrier.
I nt h i sr e p o r t ,w eu s et h eG L 2 6 1 - c e l lb a s e dm o u s em o d e lo f
malignant glioma, as well as human glioma (grade 2–4), to investigate
the hypothesis that Th17 cells infiltrate brain tumors. We report that
mRNA for the Th17 cytokine, IL-17A, is expressed in immunocom-
petent mice with glioma, but not in Rag1
2/2 immunodeficient mice
with glioma. Furthermore, mRNA for the Th17-inducing cytokines,
IL-6 and TGF-b,a sw e l la st h eT h 1 7 - a c t i v a t i n gc y t o k i n e ,I L - 2 3 ,i s
expressed in immunocompetent mice with glioma. Additionally,
Th17 were detectable in mouse draining lymph nodes (dLN) and
glioma. Importantly, mRNA expression for the Th17 cytokine, IL-
17A, is increased in human glioma relative to normal human brain
and Th17 cells are present in GBM. Collectively, the results suggest
that Th17 cells infiltrate human and mouse glioma.
Materials and Methods
Animals
Six to eight-week old male C57BL/6 (stock # 000664) and
Rag1KO (stock # 002216) mice were obtained from Jackson
Laboratories (Bar Harbor, ME) and maintained in a specific
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procedures were completed in accordance with NIH (National
Institutes of Health) guidelines on the care and use of laboratory
animals for research purposes. The protocol was approved by the
Institutional Committee on Animal Use at the University of
Chicago.
GL261 cell line
GL261 murine glioma cells were cultured in Dulbecco’s
modified Eagle medium supplemented with 10% fetal calf serum,
as well as streptomycin (100 mg/ml) and penicillin (100 U/ml) at
37uC in a humidified atmosphere of 95% air/5% CO2.
Mouse intracranial injection model
Mice were anesthetized with an intraperitoneal injection of
0.1 ml of a stock solution containing ketamine HCl (25 mg/ml),
xylazine(2.5 mg/ml),and 14.25%ethylalcohol(diluted 1:3in0.9%
NaCl). For the stereotactic intracranial injection, the surgical site
wasshavedandprepared with70%ethylalcohol.Amidlineincision
was made, and a 1 mm diameter right parietal burr hole, centered
2 mm posterior to the coronal suture and 2 mm lateral to the
sagittal suture, was drilled. Mice were placed in a stereotactic frame
and 2.5 mL PBS or 4610
5 GL261 cells in 2.5 mL PBS was injected
intracranially with a 26-gauge needle at a depth of 3 mm. The
needle was removed and theskinwassutured with 4-0nylon thread.
Patient samples
Resected specimens from patients who underwent operations in
the Section of Neurosurgery at the University of Chicago Medical
Center between 2009 and 2010 were evaluated in this study.
According to the WHO classification, samples included normal
brain, grade II astrocytoma, grade III oligodendroglioma, and
GBM. Normal brain control tissue consisted of non-malignant
tissue obtained during resection from a patient with glioma.
Histological confirmation of the diagnosis for tumors was obtained
in all cases by an attending neuropathologist. The tissue was
collected in accordance with a protocol approved by the
Institutional Review Board (IRB) at the University of Chicago.
RNA isolation, semi-quantitative PCR and real-time PCR
Total cellular RNAfrom normalWT mouse brain(n=3),3 week
post-operative (WPO) PBS-injected WT mouse brain (n=6), 3
WPO WT mouse brain with glioma (n=6) and 3 WPO Rag1
2/2
mouse brain with glioma (n=3) or normal human brain (n=3),
human astrocytoma (grade 2; n=3), human oligodendroglioma
(grade 3; n=1) and human glioblastoma multiforme (n=12)
was isolated using the RNeasy Mini kit (Qiagen; Valencia, CA)
according to the manufacturer’s protocol. Equivalent amounts of
RNA were reverse-transcribed with the iScript cDNA Synthesis Kit
(Bio-rad Laboratories; Hercules, CA). Semi-quantitative PCR was
performed using 5 uL Taq PCR Master Mix, 2.5 mM forward
primer, 2.5 mM reverse primer, 2 uL RNase-free H2O and 1 ng
input cDNA per reaction. Amplification was performed using the
iCycler Thermal Cycler (Bio-Rad Laboratories) under the following
conditions: 3 min at 95uC, followed by 30 cycles of 30 sec at 95uC,
30 secat60uCand30 secat72uC,followedby5 min at72uC.PCR
products combined with 2 uL 6X DNA Loading Dye (Fermentas
Life Sciences; Glen Burnie, MD) were ran on a 2% agarose gel with
the GeneRuler 100 bp DNA ladder. The gel was visualized in the
ChemiDoc XRS Universal Hood II (Bio-rad Laboratories). Real-
time PCR was performed using 5 uL SYBR GreenER qPCR
Supermix Universal (Invitrogen; Carlsbad, CA), 0.5 mM forward
primer, 0.5 mM reverse primer, 3 uL RNase-free H2O and 1 ng
input cDNA per reaction. Amplification and detection was
performed using the Opticon 2 Real-Time PCR Detector (Bio-
rad Laboratories) using Opticon Monitor software (version 3.1.32;
Bio-rad Laboratories) under the following conditions: 15 min hot
start at 95uC, 15 sec denaturation at 95uC, 20 sec annealing of
primers at 60uC, and 15 sec elongation at 72uC, for 35 cycles.
Triplicate reactions were performed for all cDNA samples. For
mouse and human samples, percent change in mRNA levels was
calculated using the formulas ((Experimental group/PBS group)
6100)) – 100% and ((Glioma/Normal brain) 6100)) – 100%,
respectively. Mouse and human primer sequences used for PCR
reactions are found in Tables 1 and 2, respectively.
Histology and immunofluorescence
At 3 WPO, WT mouse brains with glioma were flash frozen [in
62.5% n-Butyl Bromide (Fisher Scientific; Pittsburgh, PA) +37.5%
2-methylbutane (Fisher Scientific) surrounded by crushed dry ice]
as previously described [14,15,16]. Briefly, frozen brains were
sectioned at a temperature of 224uC and immersed into Tissue
Teck O.C.T. Compound (Sakura Finetek USA, Inc., Torrance,
CA) at 8 mm intervals and thaw-mounted onto pre-cleaned
SuperFrost slides (Fisher Scientific). Sections were post-fixed with
4% paraformaldehyde, blocked for endogenous biotin for 5 min
(1% H2O2 in PBS), and blocked for non-specific staining with 10%
bovine serum albumin (A4503; Sigma-Aldrich; Saint Louis, MO)
in PBS for 1 hr. Sections were incubated with either or the 3
antibody combinations which consisted of i) anti-GFAP-alexa fluor
488 (131-17719; Invitrogen) and biotinylated anti-CD11b (M1/
70.15; Invitrogen), ii) anti-CD11c-alexa fluor 488 (N418;
Ebioscience; San Diego, CA) and anti-CD11b (M1/70.15;
Invitrogen) or iii) anti-CD4-alexa fluor 647 (GK1.5; Ebioscience)
and biotinylated anti-FoxP3 (FJK-16S; Ebioscience) in PBS at 4uC
Table 1. Mouse primer sequences.
Gene symbol GenBank accession Forward primer 59R39 Reverse primer 59R39 Amplicon size (bp)
IL-17A NM_010552.3 CTCAAAGCTCAGCGTGTCCAAACA TATCAGGGTCTTCATTGCGGTGGA 130
TGF-b NM_011577.1 CACTGATACGCCTGAGTG GTGAGCGCTGAATCGAAA 100
IL-23 NM_031252.2 AACAGCTTAAGGATGCCCAGGTTC ATAATGGTGTCCTTGCCCTTCACG 143
IL-6 NM_031168.1 TGGCTAAGGACCAAGACCATCCAA AACGCACTAGGTTTGCCGAGTAGA 93
CD3e NM_007648.4 ACCTGAAAGCTCGAGTGTGTGAGT TGGCCTTCCTATTCTTGCTCCAGT 135
GAPDH NM_008084.2 TCAACAGCAACTCCCACTCTTCCA ACCCTGTTGCTGTAGCCGTATTCA 115
The gene symbols used above indicate: IL-17A = interleukin-17A; TGF-b = transforming growth factor-beta; IL-23= interleukin-23; IL-6= interleukin-6; CD3e= CD3
antigen, epsilon polypeptide; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0015390.t001
Th17 Cells in Glioma
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streptavidin-alexa fluor 555 for 2.5 hr. Following extensive
washing in PBS, sections were covered with Ultra Cruz mounting
media (Santa Cruz; Santa Cruz, CA). Images of antibody-stained
sections were captured using the Sp5 2-photon laser scanning
confocal microscope (Leica; Mannheim, Germany). Fluorescent
images were captured using the 636 objective. Additionally, 3
WPO mouse brains with glioma were stained with hematoxylin
and eosin (H&E) to visualize tumor size and location. Images of
H&E staining were photographed using the 1.256objective of the
Axioskop (Zeiss; Chester, VA) microscope running Openlab
software.
Table 2. Human primer sequences.
Gene symbol GenBank accession Forward primer 59R39 Reverse primer 59R39 Amplicon size (bp)
IL-17A NM_002190.2 CCACGAAATCCAGGATGCCCAAAT ATTCCAAGGTGAGGTGGATCGGTT 144
CD3e NM_000733.3 TTCTGGCCTGAATCAGAGACGCAT TTCACCATGAGGCTGAGGAACGAT 150
GAPDH NM_002046.3 TCTCCTCTGACTTCAACAGCGACA GACAAAGTGGTCGTTGAGGGCAAT 80
The gene symbols used above indicate: IL-17A= interleukin-17A; CD3e= CD3 antigen, epsilon polypeptide; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0015390.t002
Figure 1. A mouse brain that received an intracranial injection of GL261 cells. At three weeks post-operatively. (A) Hematoxylin and eosin
staining of mouse glioma at 3 weeks post-operatively. Scale bar =1 mm. (B) GFAP (green), CD11b (red) and DAPI (blue) immunofluorescence along
the border between mouse brain parenchyma and glioma. Scale bar =50 mM. (C) CD11c (green), CD11b (red), and DAPI (blue) immunofluorescence
in the mouse glioma. Scale bar =50 mM. (D) CD4 (green) and FoxP3 (red) immunofluorescence in the mouse glioma. Tailed arrows indicate
CD4
+FoxP3
2 cells, while untailed arrows indicate CD4
+FoxP3
+ T regulatory cells. Scale bar =25 mM.
doi:10.1371/journal.pone.0015390.g001
Th17 Cells in Glioma
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analysis
Brain and cervical (draining) lymph node cell suspensions were
prepared from 3 WPO PBS-injected WT mice (n=3), 3 WPO
WT mice with glioma (n=3) and human GBM (n=2). Red blood
cells were removed by treatment with ACK Lysis Buffer (Lonza,
Walkersville, MD) for four minutes at 4uC. Cells were incubated
with phorbol myristate acetate (PMA, 50 ng/ml, Sigma; St. Louis,
MO) and ionomycin (500 ng/ml, Sigma, St. Louis, MO) for 4 h in
the presence of GolgiBlock (1 mL/mL, Becton Dickenson (BD);
Franklin Lakes, NJ). 1610
6 cells were stained with anti-CD4-
pacific blue (RM4-5; Ebioscience) or anti-CD4-FITC (RPA-T4;
BD) for mouse and human cells, respectively, for 30 min on ice.
Cells were permeabilized, fixed and stained on ice using the
Cytofix/Cytoperm buffer (BD) according to the manufacturer’s
instructions with anti-IL-17A-FITC (eBio17B7; isotype, rat IgG2A)
biotinlyated anti-IFN-c (XMG1.2; isotype, rat IgG1), anti-FoxP3-
APC (FJK-16S; isotype, rat IgG2A) and anti-IL-4-PE (BVD4-
1D11; isotype, rat IgG2B) for mouse cells or anti-IL-17A-APC
(eBio64DEC17; isotype mouse IgG1) for human cells, respectively.
Mouse cells were subsequently incubated with streptavidin-PerCP
for 20 min on ice. The cellular frequency was determined by the
LSR II flow cytometry device (Becton-Dickinson) and Flowjo
analysis software (TreeStar, Cupertino, CA). Intracellular anti-
bodies and streptavidin-PerCP were either purchased from
Ebioscience of BD.
Statistical analysis
All data are presented as means 6 standard error of
measurement (SEM). The results from the experiments were
analyzed using GB-STAT School Pak (Dynamic Microsystems,
Inc.; Silver Spring, MD). For statistical comparisons, data were
analyzed using the 2-way analysis of variance (ANOVA) method,
followed by post hoc comparisons using the Newman-Keuls test.
Results
An experimental mouse model of glioma
As shown in Fig. 1, GL261-cell based glioma takes up a large
volume of intracranial space at 3 weeks post-operative (WPO) in
the mouse brain. Additionally, reactive GFAP
+ astrocytes and
CD11b
+ microglia/macrophages form a glial border around the
glioma. Furthermore, CD11b
+ and CD11c
+ antigen presenting
cells are found clustered together in the glioma. Similarly,
Figure 2. Th17-related mRNA expression levels in mouse brain with or without a GL261 cell injection. (A) PCR products for IL-17A and
GAPDH from control (Normal) mouse brain or 3 week post-operative wild-type (WT) mouse brain that received an intracranial (IC) injection of PBS, WT
mouse brain that received an IC injection of 4610
5 GL261 cells (Glioma) or recombinase activating gene 1-deficient (Rag1
2/2) mouse brain that
received an IC injection of 4610
5 GL261 cells (Rag1
2/2). Individual mice are differentiated by numbers 1–3. (B) IL-23 mRNA levels are displayed as the
percent change between the experimental group (Exp.) and the mouse brain that received an IC injection of PBS (PBS), normalized to GAPDH. (C)
TGF-b1 mRNA levels are displayed as the percent change between the experimental group (Exp.) and the mouse brain that received an IC injection of
PBS (PBS), normalized to GAPDH. (D) IL-6 mRNA levels are displayed as the percent change between the experimental group (Exp.) and the mouse
brain that received an IC injection of PBS (PBS), normalized to GAPDH. (E) CD3e mRNA levels are displayed as the percent change between the
experimental group (Exp.) and the mouse brain that received an IC injection of PBS (PBS), normalized to GAPDH. Bar heights represent means
(6SEM). ND=not detectable.
doi:10.1371/journal.pone.0015390.g002
Th17 Cells in Glioma
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+FoxP3
2 T helper and CD4
+FoxP3
+ T regulatory cells are
found clustered together in the glioma. Thus, mouse glioma is
comprised of many types of cells closely juxtaposed around- and
intermixed throughout- the malignancy.
Th17-secreted, activating and inducing cytokine levels
are increased in glioma
To determine if IL-17A mRNA is increased in mouse glioma,
normal mouse brain, PBS-injected WT mouse brain, WT mouse
brain with glioma and Rag1
2/2 (lack functional T and B cells)
mouse brain with glioma were analyzed (Fig. 2A). IL-17A mRNA is
not detectable in normal mouse brain or mouse brain injected with
PBS. However, IL-17A mRNA is detectable in glioma of WT mice,
but not in glioma of Rag1
2/2 mice. Furthermore, mRNA levels are
unchanged fortheTh17-activatingcytokine, IL-23,innormal, WT-
glioma and Rag1
2/2-glioma mouse brain (33651%, 216.3665%
and 102696%, respectively). In addition, although mRNA for the
Th17-inducing cytokine, TGF-b, is not detectable in normal mouse
brain, it is induced in WT-glioma and Rag1
2/2-glioma mouse
brain (5066171% and 6626319%, respectively). In contrast,
mRNA levels for the Th17-inducing cytokine, IL-6, is 67653%
in normal mouse brain and increases in WT-glioma and Rag1
2/2-
glioma mouse brain (6186316% and 356667%, respectively).
Finally, although mRNA for the T cell-specific complex, CD3e,i s
not detectable in normal or Rag1
2/2-glioma mouse brain, it is
induced in WT-glioma mouse brain (736762570%). These data
suggest that glioma-induced mRNA expression for the Th17
cytokine, IL-17A, as well as T cell infiltration represented by
CD3e, requires both the presence of malignancy, as well as a
functional immune system. In addition, the presence of glioma
appears to increase the Th17-inducing cytokines, TGF-b and IL-6.
Th17 cells are present in glioma and draining lymph
nodes
To determine if Th17 cells develop in glioma-draining lymph
node (dLN) and are present in mouse glioma, PBS-dLN, glioma-
Figure 3. Th17 cell phenotype in dLN and mouse brain with or without a GL261 cell injection. (A) Analysis of draining lymph nodes for
CD4
+IgG2A
+ (isotype control) or CD4
+IL-17A
+ cells in mice that received an intracranial (IC) injection of PBS or 4610
5 GL261 cells (Glioma). (B) Analysis
of brains for CD4
+IgG2A
+ (isotype control) or CD4
+IL-17A
+ cells in mice that received an IC injection of PBS or 4610
5 GL261 cells (Glioma). (C) Average
CD4
+IL-17A
+ cell frequency in dLNs or brains (6SEM). (D) Analysis of brains for CD4
+IL-17A
+IgG1
+ (isotype control) or CD4
+IL-17A
+IFN-c
+ cells (1
st
row), CD4
+IL-17A
+IgG2A
+ (isotype control) or CD4
+IL-17A
+FoxP3
+ cells (2
nd row) and CD4
+IL-17A
+IgG2B
+ (isotype control) or CD4
+IL-17A
+IL-4
+ cells (4
th
row) in mice that received an intracranial injection of PBS or 4610
5 GL261 cells (Glioma). (E) Average CD4
+IL-17A
+IFN-c
+, CD4
+IL-17A
+FoxP3
+, and
CD4
+IL-17A
+IL-4
+ cell frequency in brains (6SEM). Data are representative of at least 2 independent experiments. * and ** denotes significant
differences at p#0.05 and p#0.01, respectively.
doi:10.1371/journal.pone.0015390.g003
Th17 Cells in Glioma
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operative in WT mice. As shown in Fig. 3A-C, a two-way
ANOVA for changes in CD4
+IL-17
+ T cell frequency revealed a
main effect between mice with or without glioma [F(1,11)=8.55,
p=0.0192]. Isotype control cells are not detectable in mouse dLN
and brain. The average CD4
+IL-17
+ cell frequency is 1263.7%,
1261.1%, 0% and 1061.5% in PBS-dLN, glioma-dLN, PBS-
brain and glioma-brain, respectively. These data suggest that
Th17 cells are present in the mouse dLN in response to an injury
to the brain and that the level of Th17 cells is not affected by the
presence of glioma. Furthermore, these data suggest that Th17
cells are present in mouse brain due to the glioma and not in
response to an injury to the brain.
To determine if brain-derived Th17 cells share lineage plasticity
with Th1, Treg and Th2 cells, PBS- and glioma-mouse brains
were analyzed at 3 weeks post-operative in WT mice. As shown in
Fig. 3D-E, a two-way ANOVA for changes in CD4
+IL-17
+IFN-
c
+, CD4
+IL-17
+FoxP3
+ and CD4
+IL-17
+IL-4
+ T cell frequency
revealed a main effect of treatment [F(1,17)=24.87, p=0.0003], a
main effect of multi-lineage Th17 cells [F(1,17)=4.33, p=0.0383]
and an interaction between treatment and multi-lineage Th17 cells
[F(1,17)=4.33, p=0.0383]. Isotype control cells are not detectable
in mouse brains. The average frequency of Th17 that co-expressed
IFN-c, FoxP3 and IL-4 increased from 0%, 0%, and 0% in PBS-
brains to 1064%, 2265% and 463%, in glioma brains,
respectively. These data suggest that glioma affects the lineage
specificity of Th17 cells.
IL-17A mRNA and Th17 cells in human glioma
To determine if IL-17A mRNA is increased in human glioma,
normal human brain, as well as astrocytoma (grade 2),
oligodendroglioma (grade 3) and GBM were analyzed (Fig. 4A).
The level of IL-17A mRNA in astrocytoma is 778627% and
increases in oligodendroglioma and GBM (6658% and
498161344%, respectively). Additionally, the CD3e mRNA level
in astrocytoma is 9416323% and increases in oligodendroglioma
and GBM (7515% and 523161942%). When IL-17A mRNA
levels are normalized to CD3e mRNA levels, there is no difference
between astrocytoma, oligodendroglioma and GBM (20.7627%,
214% and 40635%, respectively). Finally, the frequency of
CD4
+IL-17A
+ Th17 in GBM was determined (Fig. 4D). Isotype
control cells are not detectable in GBM, while the CD4
+IL-17
+
cell frequency is 17%. Collectively, the data indicate that Th17 are
present in human glioma and that the expression of the Th17
cytokine, IL-17A, as well as the number of T cells, is increased in
oligodendroglioma and GBM, compared to low-grade astrocyto-
ma. However, IL-17A expression appears to be dependent on T
cell accumulation, since IL-17A mRNA levels were not different
between types of human glioma, when normalized to CD3e
mRNA levels.
Figure 4. Th17-related mRNA expression levels and Th17 cells in human glioma. (A) IL-17A mRNA levels are displayed as the percent
change between the glioma group (Glioma) and normal human brain (Normal), normalized to GAPDH. (B) CD3e mRNA levels are displayed as the
percent change between the glioma groups (Glioma), astrocytoma (grade 2; Astro), oligodendroglioma (grade 3; Oligo), glioblastoma multiforme
(GBM) and normal human brain (Normal), normalized to GAPDH. (C) IL-17A mRNA levels are displayed as the percent change between the glioma
groups (Glioma), astrocytoma (grade 2; Astro), oligodendroglioma (grade 3; Oligo), glioblastoma multiforme (GBM) and normal human brain
(Normal), normalized to CD3e. (D) Analysis of GBM for CD4
+IgG1
+ (isotype control) or CD4
+IL-17A
+ cells. Flow cytometry data are representative of at
least 2 independent GBM patient specimens. Bar heights represent means (6SEM).
doi:10.1371/journal.pone.0015390.g004
Th17 Cells in Glioma
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Collectively, the data demonstrate the presence of Th17 in
mouse and human glioma. However, the presence of Th17 that
co-express cytokines from other T helper lineages poses the
challenge of identifying the significance and role of multi-lineage
CD4
+ T cells. Recently, it was demonstrated in mouse tumor-
draining lymph nodes that the inhibition of indoleamine 2,3
dioxygenase (IDO) caused the conversion of Treg into a
polyfunctional T helper phenotype with Th17 properties [17].
Additionally, Treg that expand in adenomatous polyps of colon
cancer start to produce IL-17A, which results in simultaneous
immunosuppression of T helper function, while promoting tumor
progression through inflammation-driven mastocytosis [18].
Whether polyfunctional T helper cells have an equal level of
pathogenesis in glioma has yet to be explored.
From a clinical perspective, determining the effector function of
Th17 in glioma may bring novel therapeutic avenues in the field of
brain tumor immunotherapy, just as determining the role of Treg
in glioma did several years ago [2–4]. Currently, small molecule
inhibitors of Th17 [19] or inhibitors of Th17 differentiation are
currently being pursued [20]. In addition, Th17 inhibitors have
seen mixed success in human studies, failing to control relapsing
multiple sclerosis, while showing promise in patients with psoriasis
and Crohn’s disease [21]. Given the immunosuppressive nature of
the CNS, combined with the tolerogenic [22] and multi-cellular
nature of glioma, determining the role of the pro-inflammatory
Th17 is important to address.
The presence of IL-17A mRNA in human glioma was recently
identified through a large scale microarray analysis of Th1-, Th2-
and Th17-related genes [23]. However, it was neither established
whether IL-17A mRNA levels were dependent on T cell levels nor
was it identified that Th17 cells were present. This study
confirmed the presence of the Th17 cytokine, IL-17A, and
identified the presence of Th17 cells in both human and mouse
glioma. Importantly, we could not detect mRNA for the Th17-
secreted cytokine, IL-17A, in Rag1
2/2 mice with glioma,
suggesting that T or B cells are required for IL-17A expression.
In future investigations, we intend to identify whether IL-17A
expression in glioma is solely a CD4
+ T cell cytokine or if B cells
also produce this cytokine through analysis of IL-17A mRNA
levels in CD4 T cell- and B cell-deficient mice with malignant
glioma. Additionally, we will identify the in vivo role of Th17 cells
using IL-17A
2/2 or Rag1
2/2 mice with malignant glioma,
adoptively transferred CD4
+ T cells from IL-17A
2/2 mice.
Finally, we plan to compare the chemokine receptor repertoire
of glioma-resident polyfunctional T helper cells with that of
polarized T helper cell subsets. Collectively, these future
experiments will determine the role of Th17 in a pre-clinical
malignant glioma model, as well as determine whether these cells
represent a future therapeutic target in human health.
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